Discovery of Ecallantide: A potent and selective inhibitor of plasma kallikrein

被引：3
|
作者：
Ladner, R. [1 ]
Kent, R. [1 ]
Ley, A. [1 ]
Nixon, A. [1 ]
Sexton, D. [1 ]
机构：
[1] Dyax Corp, Cambridge, MA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2007年 / 119卷 / 01期
关键词：
D O I：
10.1016/j.jaci.2006.12.591
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1218
引用
收藏
页码：S312 / S312
页数：1
相关论文
共 50 条
  • [1] Ecallantide - Plasma kallikrein inhibitor, treatment of hereditary angioedema
    Revill, P.
    Mealy, N.
    DRUGS OF THE FUTURE, 2007, 32 (07) : 590 - 594
  • [2] ECALLANTIDE: A PLASMA KALLIKREIN INHIBITOR FOR THE TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA
    Stolz, L. E.
    Horn, P. T.
    DRUGS OF TODAY, 2010, 46 (08) : 547 - 555
  • [3] DEVELOPMENT OF A PLASMA KALLIKREIN SELECTIVE INHIBITOR
    OKADA, Y
    TSUDA, Y
    WANAKA, K
    HIJIKATAOKUNOMIYA, A
    OKAMOTO, S
    JOURNAL OF PHARMACOBIO-DYNAMICS, 1992, 15 (07): : S87 - S87
  • [4] Synthesis of potent and selective inhibitors of human plasma kallikrein
    Garrett, GS
    McPhail, SJ
    Tornheim, K
    Correa, PE
    McIver, JM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (03) : 301 - 306
  • [5] ACUTE ATTACKS OF ACQUIRED ANGIOEDEMA RESPONDING TO KALLIKREIN INHIBITOR (ECALLANTIDE)
    Vernon, N.
    Ghaffari, G.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2012, 109 (05) : A90 - A90
  • [6] Discovery of α-Amidobenzylboronates as Highly Potent Covalent Inhibitors of Plasma Kallikrein
    Allison, Matthew
    Davie, Rebecca L.
    Mogg, Adrian J.
    Hampton, Sally L.
    Emsley, Jonas
    Stocks, Michael J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2024, 15 (04): : 501 - 509
  • [7] Discovery of a potent and selective Aurora kinase inhibitor
    Oslob, Johan D.
    Romanowski, Michael J.
    Allen, Darin A.
    Baskaran, Subramanian
    Bui, Minna
    Elling, Robert A.
    Flanagan, William M.
    Fung, Amy D.
    Hanan, Emily J.
    Harris, Shannon
    Heumann, Stacey A.
    Hoch, Ute
    Jacobs, Jeffrey W.
    Lam, Joni
    Lawrence, Chris E.
    McDowell, Robert S.
    Nannini, Michelle A.
    Shen, Wang
    Silverman, Jeffrey A.
    Sopko, Michelle M.
    Tangonan, Bradley T.
    Teague, Juli
    Yoburn, Josh C.
    Yu, Chul H.
    Zhong, Min
    Zimmerman, Kristin M.
    O'Brien, Tom
    Lew, Willard
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (17) : 4880 - 4884
  • [8] Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor
    Schneider, Lynda
    Lumry, William
    Vegh, Arthur
    Williams, Anthony H.
    Schmalbach, Tess
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (02) : 416 - 422
  • [9] Discovery and Characterization Of a Highly Specific Antibody Inhibitor Of Plasma Kallikrein
    Kenniston, Jon A.
    Sexton, Daniel J.
    Martik, Diana
    Faucette, Ryan R.
    Viswanathan, Malini
    Kastrapeli, Niksa
    Kopacz, Kris J.
    Conley, Greg P.
    Lindberg, Allison P.
    Cosic, Janja
    Comeau, Stephen R.
    Mason, Shauna
    DiLeo, Mike
    Chen, Jie
    Ladner, Robert C.
    Edwards, Thomas E.
    TenHoor, Christopher
    Nixon, Andrew E.
    Adelman, Burt
    BLOOD, 2013, 122 (21)
  • [10] Resolution of bowel obstruction in a patient with hereditary angioedema treated with DX-88 (Ecallantide1), a potent human plasma kallikrein inhibitor:: A case study
    Cicardi, Marco
    Zingale, Lorenza C.
    Zanichelli, Andrea
    MOLECULAR IMMUNOLOGY, 2007, 44 (1-3) : 160 - 160
12345